| Literature DB >> 30746044 |
Julián Esteban Barahona-Correa1, Juan Diego Aristizabal-Mayor1, Pieralessandro Lasalvia1, Álvaro J Ruiz2,3, Patricia Hidalgo-Martínez3,4.
Abstract
OBJECTIVE: Poor sleep patterns are common in undergraduates and may turn them prone to mood disorders, substance abuse and impaired academic performance. The aim of this study was to assess sleep disturbances among medical students, and whether associations with academic performance, depressive symptoms or substance use were present.Entities:
Keywords: Latin America; Mood Disorders; Sleep; Sleep Disorders; Students, Medical; Substance-Related Disorders
Year: 2018 PMID: 30746044 PMCID: PMC6361310 DOI: 10.5935/1984-0063.20180041
Source DB: PubMed Journal: Sleep Sci ISSN: 1984-0063
General characteristics of total surveyed population and by questionnaire.
| Variable [n (%)] | Total (n=544) | PQSI (n=300) | ESS (n=471) | BQ (n=544) | |
|---|---|---|---|---|---|
| Age | |||||
| <16 | 5 (1) | 4 (1) | 5 (1) | 5 (1) | 0.96 |
| 16-18 | 138 (25) | 80 (27) | 121 (26) | 138 (25) | |
| 19-21 | 274 (50) | 161 (54) | 244 (52) | 274 (50) | |
| 22-24 | 103 (19) | 48 (16) | 85 (18) | 103 (19) | |
| >25 | 8 (2) | 2 (1) | 8 (2) | 8 (2) | |
| ND | 16 (3) | 5 (2) | 8 (2) | 16 (3) | |
| Gender | |||||
| Male | 197 (36) | 110 (37) | 173 (37) | 197 (36) | 0.88 |
| Female | 296 (54) | 170 (57) | 259 (55) | 296 (54) | |
| ND | 51 (9) | 20 (7) | 39 (8) | 51 (9) | |
| Currently working | |||||
| Yes | 15 (3) | 10 (3) | 10 (2) | 15 (3) | 0.25 |
| No | 513 (94) | 287 (96) | 455 (97) | 513 (94) | |
| ND | 16 (3) | 3 (1) | 6 (1) | 16 (3) | |
| Study stage | |||||
| Preclinical | 325 (60) | 185 (62) | 281 (60) | 325 (60) | 0.94 |
| Clinical | 219 (40) | 115 (38) | 190 (40) | 219 (40) | |
| Fulfilled DSM-IV Depression Criteria (n=529) | |||||
| Yes | 139 (26) | - | - | - | - |
| No | 390 (74) | - | - | - | |
| GPA (n=450) | |||||
| <4 | 227 (50) | - | - | - | - |
| >4 | 223 (50) | - | - | - |
Available complete questionnaires/answers.
Abbreviations: PSQI Pittsburgh Sleep Quality Index; ESS Epworth Sleepiness Scale; BQ Berlin Questionnaire; ND No data.
General characteristics by questionnaire score.
| Variable [ n (%)] | PSQI (n=300) | ESS (n=471) | BQ (n=544) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| <5 | >5 | <10 | >10 | Low risk | High risk | ||||
| Age | |||||||||
| <16 | 3 (75) | 1 (25) | 0.02 | 2 (40) | 3 (60) | 0.69 | 5 (100) | 0 (0) | 0.38 |
| 16-18 | 38 (47) | 42 (53) | 46 (38) | 75 (62) | 125 (91) | 13 (9) | |||
| 19-21 | 48 (30) | 113 (70) | 86 (35) | 158 (65) | 251 (92) | 23 (8) | |||
| 22-24 | 13 (27) | 35 (73) | 24 (28) | 61 (72) | 87 (85) | 16 (15) | |||
| >25 | - | 2 (100) | 3 (37) | 5 (63) | 7 (88) | 1 (12) | |||
| ND | 1 (20) | 4 (80) | 4 (50) | 4 (50) | 15 (94) | 1 (6) | |||
| Gender | |||||||||
| Male | 42 (38) | 68 (62) | 0.25 | 73 (42) | 100 (58) | 0.036 | 167 (85) | 30 (15) | 0.028 |
| Female | 52 (31) | 118 (69) | 75 (29) | 184(71) | 275 (93) | 21 (7) | |||
| ND | 9 (45) | 11 (55) | 17 (44) | 22 (56) | 48 (94) | 3 (6) | |||
| Currently working | |||||||||
| Yes | 2 (20) | 8 (80) | 0.62 | 4 (40) | 6 (60) | 0.94 | 14 (93) | 1 (7) | 0.80 |
| No | 100 (35) | 187 (65) | 159 (35) | 296 (65) | 461 (90) | 52 (10) | |||
| ND | 1 (33) | 2 (67) | 2 (33) | 4 (67) | 15 (94) | 1 (6) | |||
| Study stage | |||||||||
| Preclinical | 68 (37) | 117 (63) | 0.26 | 107 (38) | 174 (62) | 0.09 | 297 (91) | 28 (9) | 0.21 |
| Clinical | 35 (30) | 80 (70) | 58 (30) | 132 (70) | 193 (88) | 26 (12) | |||
Available complete questionnaires.
Significant after Bonferroni's correction.
After a significant p-value by Chi square test was obtained, Fisher's exact test was performed to determine which subgroups differed significantly.
**Values were calculated on available questionnaires for both variables.
Abbreviations: PSQI Pittsburgh Sleep Quality Index; ESS Epworth Sleepiness Scale; BQ Berlin Questionnaire; ND No data
Figure 1Distribution of PSQI by semester. A score of more than 5 in Pittsburgh Sleep Quality Index (PSQI) define bad sleepers.
Figure 2Depressive symptoms and GPA>4 distribution by PSQI. Solid line denotes depressive symptoms. Dotted line denotes GPA >4. Abbreviations: GPA Grade Point Average, PSQI Pittsburgh Sleep Quality Index.
Depressive symptoms and GPA score by questionnaire score.
| Variable | PSQI (n=296) | Epworth (n=464) | Berlin (n=529) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n (%) | <5 | >5 | <10 | >10 | Low risk | High risk | |||
| Fulfilled DSM-IV Depression Criteria | |||||||||
| Yes | 4 (4) | 117 (40) | <0.0001 | 26 (16) | 98 (32) | 0.001 | 114 (24) | 25 (47) | 0.002 |
| No | 97 (96) | 78 (60) | 135 (84) | 205 (68) | 362 (76) | 28 (53) | |||
| GPA | |||||||||
| <4 | 29 (33) | 94 (57) | 0.001 | 52 (38) | 145 (55) | 0.002 | 193 (47) | 34 (74) | 0.002 |
| >4 | 59 (67) | 72 (43) | 86 (62) | 119 (45) | 211 (52) | 12 (26) | |||
| Total Available (%)[ | 254 (86) | 402 (87) | 450 (85) | ||||||
Available complete questionnaires.
Significant after Bonferroni's correction.
As some individuals did not answer all the questions, only complete questionnaires with available GPA were included.
Regarding DSM-IV Depression Criteria all data were available.
Abbreviations: GPA Grade point average; PSQI Pittsburgh Sleep Quality Index; ESS Epworth Sleepiness Scale; BQ Berlin Questionnaire; ND No data.
Figure 3Substance exposure at least once in the last month. Stimulants include methylphenidate - Ritalin, methamphetamine - “Meth”. Tranquilizers include diazepam, lorazepam, alprazolam, clonazepam, etc.
General characteristics by substance*.
| Variable[n (%)] | Tobacco (n=530) | Alcohol (n=509) | Binge drink(n=524) | Energy drinks(n=516) | Marihuana (n=526) | Cocaine(n=524) | Stimulants[ | Tranquilizers[ |
|---|---|---|---|---|---|---|---|---|
| General popu-lation | 103 (19) | 402 (79) | 197 (38) | 166 (32) | 52 (10) | 4 (0.8) | 12 (2) | 11 (2) |
| Age | ||||||||
| <16 | - | 4 (1) | 2 (40) | 3 (2) | 1 (2) | - | - | - |
| 16-18 | 19 (18) | 90 (22) | 50 (37) | 35 (21) | 11 (21) | 2 (50) | 1 (8) | 3 (27) |
| 19-21 | 52 (50) | 208 (52) | 100 (37) | 78 (47) | 32 (62) | 2 (50) | 6 (50) | 3 (27) |
| 22-24 | 27 (26) | 84 (21) | 40 (42) | 46 (28) | 7 (14) | - | 5 (42) | 5 (45) |
| 25 + | 3 (3) | 6 (2) | 2 (25) | 2 (1) | - | - | - | - |
| ND | 2 (2) | 10 (3) | 3 (25) | 2 (1) | 1 (2) | - | - | - |
| Gender | ||||||||
| Male | 51 (50) | 162 (40) | 90 (47) | 71 (43) | 29 (56) | 2 (50) | 6 (50) | 5 (45) |
| Female | 45 (44) | 203 (51) | 92 (32) | 77 (46) | 17 (33) | 2 (50) | 5 (42) | 5 (45) |
| ND | 7 (7) | 37 (9) | 15 (34) | 18 (11) | 6 (12) | - | 1 (8) | 1 (9) |
| Study stage | ||||||||
| Preclinical | 56 (54) | 232 (58) | 118 (38) | 88 (53) | 34 (65) | 3 (75) | 6 (50) | 6 (54) |
| Clinical | 47 (46) | 170 (42) | 79 (37) | 78 (47) | 18 (35) | 1 (25) | 6 (50) | 5 (45) |
Every exposure is measured as at least one episode in the last month. Only available responses were included, which explains the difference in sample sizes for each substance.
Stimulants includes Methylphenidate - Ritalin, Methamphetamine - "Meth"; Tranquilizers includes Diazepam, Lorazepam, Alprazolam, Clonazepam, etc.
Abbreviations: ND No data.
Substance use at least once in the last month by questionnaire score*.
| Variable | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| <5 | >5 | <10 | >10 | Low | High | ||||
| Tobacco | 14 (14) | 42 (21) | 0.1187 | 26 (16) | 60 (20) | 0.3807 | 88 (18) | 15 (28) | 0.1052 |
| Alcohol | 77 (79) | 145 (77) | 0.7639 | 123 (78) | 226 (78) | 0.9055 | 357 (78) | 45 (86) | 0.2079 |
| Binge drink | 30 (29) | 79 (40) | 0.0757 | 50 (31) | 121 (40) | 0.0682 | 176 (37) | 21 (40) | 0.7662 |
| Energy drinks | 18 (17) | 72 (37) | 0.002 | 42 (26) | 101 (34) | 0.0730 | 142 (30) | 24 (47) | 0.0260 |
| Marihuana | 6 (6) | 21 (11) | 0.2046 | 16 (10) | 28 (9) | 0.8691 | 41 (9) | 11 (21) | 0.0112 |
| Cocaine | - | 2 (1) | 0.5461 | - | 2 (1) | 0.5432 | 4 (1) | - | 0.9999 |
| Stimulants[ | - | 6 (3) | 0.964 | 3 (2) | 8 (3) | 0.7542 | 10 (2) | 2 (4) | 0.3344 |
| Tranquilizers[ | - | 4 (2) | 0.3022 | 3 (2) | 6 (2) | 0.9999 | 11 (2) | - | 0.6136 |
Values were calculated on available questionnaires for both variables.
Significant after Bonferroni's correction
Stimulants includes Methylphenidate - Ritalin, Methamphetamine - "Meth"; Tranquilizers includes Diazepam, Lorazepam, Alprazolam, Clonazepam, etc.
Abbreviations: PSQI Pittsburgh Sleep Quality Index; ESS Epworth Sleepiness Scale; BQ Berlin Questionnaire; ND No data.